A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of people diagnosed ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...

Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...

By Kamal Choudhury and Mariam Sunny Feb 20 (Reuters) - Grail's shares plunged nearly 50% on Friday after the company said ...